AJMC January 26, 2022
Skylar Jeremias

Payer intervention, lack of patient savings, and confusion surrounding interchangeability are some of the many barriers standing in the way of US biosimilar uptake, with our group of panelists calling for big changes.

Big changes are needed to overcome barriers to US biosimilar adoption, including those involving payers intervening in formulary decisions, confusion regarding interchangeability, and issues with disseminating biosimilar education, according to panelists in a recent webinar.

The webinar, titled “What’s the Hold-Up? Overcoming Barriers to the Use of Biosimilars,” was presented by The Center for Biosimilars® and sponsored by Samsung Bioepis. During the discussion, moderated by Tony Hagen, senior editor at The Center for Biosimilars®, the panelists examined some of the major barriers to biosimilar adoption in the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
How GLP-1’s moved from research labs to national TV
Understanding the politics of drug pricing in the United States
Opinion: Oprah kicked off a national conversation on obesity and GLP-1 drugs. Let’s have it
Brazil’s plan for low-cost CAR-Ts

Share This Article